イスラエルでの血液腫瘍科に最適なクリニックと費用をご発見ください2026

Israel is a global leader in hematology-oncology for blood cancer treatment. Top centers like Sourasky Medical Center report a 90% success rate in oncology. Patients access advanced therapies like CAR T-cell and bone marrow transplants faster than in many other countries. Facilities hold prestigious Joint Commission International (JCI) accreditation.

• Treatment innovation: Clinics provide early access to CAR T-cell therapy and precision medicine protocols.
• Success rates: Sourasky Medical Center reports a 90% average success rate for oncology cases.
• Expert specialists: Doctors like Dr. Polina Stepensky have performed over 3,500 bone marrow transplants.
• Rapid diagnostics: Centers often complete complex diagnostic protocols and staging within 1 to 2 weeks.

Bookimed Expert Insight: Our data shows that top Israeli hospitals like Sheba and Sourasky operate at massive scales. Sheba handles 1,500,000+ patients annually across 1,990 specialties. This high volume allows doctors to gain deep experience in rare blood cancers. We notice patients often choose these centers specifically for complex cases that other systems might turn away.

Patient Consensus: Patients note that initial consultations happen much faster in Israel than in Europe or North America. They emphasize the importance of requesting itemized costs and planning for multiple trips for treatment evaluations.

Advanced blood cancer treatments in Israel include CAR T-cell therapy, targeted molecular therapies, and hematopoietic stem cell transplantation. These options treat aggressive lymphomas, multiple myeloma, and leukemias. Leading centers offer precision medicine and haploidentical transplants. Specialized care is available for both adult and pediatric patients.

• CAR T-cell therapy: Genetically modifies T-cells to target cancer. It costs $84,000 to $89,400.
• Stem cell transplants: Includes allogeneic and autologous types. These procedures cost $79,000 to $167,000.
• Targeted therapies: Uses BTK and FLT3 inhibitors. These focus on specific genetic mutations in cancer cells.
• Advanced diagnostics: Employs MRI, CT, and biopsy. Specialist consultations range from $300 to $500.

Bookimed Expert Insight: Israeli hematology centers show a unique pattern of high-volume specialization. Dr. Polina Stepensky at Hadassah Medical Center has performed 3,500+ bone marrow transplants. Sheba Medical Center has over 35 years of experience in this field. This deep expertise allows these clinics to manage rare blood diseases that other facilities might not handle routinely.

Patient Consensus: Patients note that Israeli doctors prioritize aggressive treatment and clinical trials over passive monitoring. They emphasize the importance of quick coordination for urgent procedures like CAR T-cell therapy.

Israeli oncologists determine treatment regimens through multidisciplinary tumor boards and advanced genomic profiling. Specialists at JCI-accredited centers like Sourasky Medical Center (Ichilov) and Hadassah Medical Center align protocols with international standards. Decisions integrate molecular diagnostics, patient age, and clinical trial eligibility to personalize care plans.

• Multidisciplinary review: Teams of hematologists, surgeons, and radiologists vote weekly on complex cases.
• Genomic profiling: Next-generation sequencing often delivers results within 2 weeks to guide targeted therapy.
• Clinical precision: Doctors like Dr. Arnon Nagler Md pioneer protocols like reduced-intensity allogeneic transplantation.
• Protocol alignment: Treatment follows evidence-based guidelines from ASCO and the Israeli Ministry of Health.

Bookimed Expert Insight: Israeli oncology stands out because top specialists often hold dual roles as researchers and clinicians. At Hadassah Medical Center, Dr. Polina Stepensky has performed 3,500+ transplants, directly applying lab innovations to patient bedside care. This crossover allows patients to access experimental therapies, like CAR-T, much faster than in many European systems.

Patient Consensus: Patients emphasize that genomic testing is fast-tracked and essential for choosing the right drugs. Many note that bringing family to consultations is culturally expected and helps in making shared treatment decisions.

Eligibility for clinical trials in Israel depends on specific inclusion criteria like age, disease stage, and genetic markers. Patients often qualify for hematology oncology trials at JCI-accredited centers. These facilities use advanced protocols for leukemia, lymphoma, and multiple myeloma including CAR T-cell therapy.

• Medical status: Protocols often require an ECOG performance status of 0 or 1.
• Age requirements: Many oncology trials set an upper age limit of 70 years.
• Genetic profiling: On-site genetic re-testing frequently unlocks eligibility for rare mutation trials.
• Regulatory approval: All trials require institutional Helsinki Committee and Ministry of Health clearance.
• Compassionate access: Patients not meeting trial criteria may receive experimental drugs through expanded access.

Bookimed Expert Insight: Data from Hadassah and Sourasky (Ichilov) shows that patients with rare mutations often secure compassionate use slots even if standard trials are full. Specialists like Dr. Ilia Kirshner have led phase III trials, and choosing a clinic with high surgical volumes, like Sourasky performance of over 1,800,000 patient visits annually, often provides better access to emerging protocols.

Patient Consensus: Patients note that contacting principal investigators directly with full pathology reports speeds up the process. Many suggest budgeting for a 2-week screening trip as on-site testing often reveals new eligibility options.

Hematology oncology treatment in Israel starts within 1 to 7 days for urgent cases. Routine procedures typically begin within 7 to 10 days of arrival. JCI-accredited centers like Sourasky Medical Center (Ichilov) use fast-track programs to accelerate diagnostics for international patients.

• Urgent cases: Treatment for acute conditions often begins within 1 to 3 days.
• Initial consultation: Patients usually meet oncologists within 24 to 48 hours after arrival.
• Diagnostic window: Biopsies and PET-CT scans are typically completed within 3 to 5 days.
• Bone marrow transplant: Procedures can be greenlit within 72 hours if donors are pre-identified.

Bookimed Expert Insight: High-volume centers like Sheba Medical Center handle over 1.5 million patients annually. Their massive infrastructure allows them to operate in-house cord blood banks and specialized labs. This independence from external providers often cuts the waiting time for complex cell therapies by several days compared to smaller facilities.

Patient Consensus: Patients note that arriving with pre-translated medical records significantly speeds up the process. They emphasize that while the medical system moves quickly, scheduling around Shabbat or local holidays is essential to avoiding minor 1-day delays.

Patients in Israel commonly experience fatigue, nausea, and low blood counts during hematology oncology treatments. Specialist centers manage these via proactive medication protocols and expert nursing support. Most side effects are temporary and respond well to clinical interventions like growth factor injections or targeted anti-emetics.

• Fatigue management: Daily injections and strict rest schedules help manage post-chemotherapy exhaustion.
• Nausea control: Preemptive medication combinations like Zofran or Kytril effectively prevent severe symptoms.
• Infection prevention: Prophylactic antibiotics and rapid emergency protocols address fevers from low white cells.
• Neuropathy relief: Early intervention with specialized medications or acupuncture eases tingling from targeted therapies.

Bookimed Expert Insight: Israeli hematology centers like Sourasky Medical Center (Ichilov) and Hadassah offer unique efficiency through home-based supportive care. Data shows clinics often coordinate nurse visits for home injections and medication delivery. This approach minimizes hospital stays and reduces the risk of secondary infections for immunocompromised patients.

Patient Consensus: Patients note that while fatigue is intense, the 24/7 clinic hotlines and walk-in access for blood transfusions provide significant peace of mind. Using Hebrew translation apps for pharmacy discussions and staying extremely hydrated are top recommendations from those treated in Israel.

Israel manages international hematopoietic stem-cell transplants and CAR-T therapies through specialized departments at JCI-accredited centers. These facilities coordinate diagnostics, cell harvesting, and intensive monitoring. Centers like Sheba Medical Center and Sourasky Medical Center provide integrated logistics including medical visa sponsorship and English-speaking staff.

• Treatment timeline: Active phases typically span 4 to 6 weeks for international patients.
• Clinical coordination: Hospitals like Hadassah Medical Center offer dedicated departments for complex cell therapies.
• Specialized expertise: Dr. Ron Ram at Sourasky has performed several hundred stem cell transplants.
• Pediatric care: Dr. Polina Stepensky at Hadassah has completed over 3,500 bone marrow transplants.

Bookimed Expert Insight: While many believe choosing a hospital is only about the surgeon, our data shows that for cell therapies, the laboratory is equally vital. Clinics like Sheba Medical Center and Sourasky Medical Center utilize on-site manufacturing labs. This capability can reduce CAR-T production time to just 10–11 days. For international patients, this shorter window significantly lowers the total cost of their stay in Israel.

Patient Consensus: Patients note it is important to start the coordination process 2 to 3 months early to secure visa sponsorship. They often suggest budgeting for 1 to 3 months of stay due to isolation rules and follow-up requirements.

Israel's premier hospitals for hematologic oncology include Sheba Medical Center, Hadassah Medical Center, and Sourasky Medical Center. These institutions hold JCI accreditation and Newsweek rankings. They specialize in high-volume marrow transplants, CAR T-cell therapy, and complex leukemia treatments for international patients.

• Sheba Medical Center: Ranked among the world's top 10 hospitals by Newsweek magazine.
• Hadassah Medical Center: Features a world-class Bone Marrow Transplantation Department in Jerusalem.
• Sourasky Medical Center: Reports an average 90% success rate for oncology treatments.
• Advanced expertise: Dr. Polina Stepensky at Hadassah has performed 3,500+ bone marrow transplants.

Bookimed Expert Insight: Data shows a strong correlation between high patient volumes and specialized success at Sheba Medical Center. It handles over 1,500,000 patients annually. This massive scale allows their specialists, like Dr. Arnon Nagler, to refine rare procedures such as cord blood transplantations. Choosing a facility with over 100 specialized departments often ensures smoother transitions between diagnostics and intensive therapy.

Patient Consensus: Patients note that central hubs in Jerusalem and Tel Aviv are preferred for complex blood disorders. They emphasize that starting the second opinion process early is vital for coordinating specialized care at these major institutions.

Israeli hematology-oncology centers follow mandatory Ministry of Health (MoH) licensing and international safety benchmarks. Leading facilities like Sheba Medical Center and Sourasky Medical Center (Ichilov) hold Joint Commission International (JCI) accreditation. These standards ensure rigorous clinical protocols and high patient safety levels.

• JCI accreditation: Signifies compliance with 300+ global safety and quality standards for clinical care.
• JACIE certification: Specialized accreditation for bone marrow transplantation clinical and laboratory activities at Hadassah.
• MoH oversight: National licensing requires advanced government exams for oncology nurses and medical staff.
• ISO standards: Laboratories often hold ISO 15189 certification for technical competence and data privacy.

Bookimed Expert Insight: Israeli centers demonstrate a unique pattern of high-volume specialty expertise. Sheba Medical Center serves 1,900,000 patients annually and performs 45,000+ operations. This massive volume allows departments to refine complex protocols like CAR T-cell therapy. Clinics with such high patient loads usually maintain the strictest infection control standards.

Patient Consensus: Patients note that Israeli oncology protocols strictly match international guidelines like NCCN. Some emphasize that top facilities maintain world-class care standards even during regional conflicts by using on-site shelters.

Suitable candidates for bone marrow transplants in Israel include patients with high-risk leukemia, multiple myeloma, or relapsed lymphoma. Doctors evaluate eligibility based on disease type, organ function, and donor availability. Israeli centers like Sourasky Medical Center (Ichilov) and Sheba Medical Center follow strict international clinical standards for selection.

• Autologous criteria: Used for multiple myeloma and relapsed Hodgkin or non-Hodgkin lymphoma.
• Allogeneic criteria: Primary for acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
• Physical fitness: Candidates typically require an ECOG performance score of 0 to 2.
• Organ health: Patients must show adequate heart, liver, and kidney function before procedure.
• Age flexibility: Reduced-intensity protocols now allow eligible patients over 65 to receive transplants.

Bookimed Expert Insight: Israeli oncology centers like Hadassah Medical Center and Sheba Medical Center provide a unique advantage by integrating local donor registries with the global National Marrow Program. This connectivity significantly increases the chance of finding a match for international patients. Furthermore, clinics with high patient volumes, such as Hadassah with 1,000,000 annual visits, often maintain specialized pediatric units for rare blood disorders.

Patient Consensus: Patients emphasize the importance of completing a full medical workup, including heart and lung tests, before arriving. Many note that preparing for a 4 to 6-week hospital stay is a practical reality of the intensive recovery process.

Recovery after stem-cell transplantation in Israel typically spans 12 to 24 months for full immune restoration. Engraftment usually occurs between days 10 and 21. Patients remain hospitalized for 3 to 6 weeks. Long-term monitoring focuses on infections and Graft-versus-Host Disease (GVHD).

• Early recovery: Engraftment begins within 2 to 6 weeks as new blood cells form.
• High-risk period: The first 100 days require intense monitoring for acute GVHD and infections.
• Immune rebound: Stabilization takes 6 to 12 months before patients can safely handle crowds.
• Side effect monitoring: Doctors track mucositis, blood counts, and long-term thyroid or fertility issues.

Bookimed Expert Insight: Israeli centers like Sheba and Hadassah achieve high volumes, performing thousands of transplants. Data shows that clinics with specialized departments, such as the one led by Dr. Ron Ram at Sourasky, often utilize in-house molecular labs. This infrastructure allows for faster detection of CMV reactivation. Detecting these regional infections early significantly improves long-term survival rates for international patients.

Patient Consensus: Patients note that mental recovery often lags behind physical healing, with many experiencing a difficult emotional period around month 3. They recommend keeping a daily symptom journal to help doctors manage steroid-induced mood swings or persistent fatigue.

Israeli medical centers provide professional interpretation and logistical support for international hematology-oncology patients. Facilities like Sourasky Medical Center and Sheba Medical Center offer dedicated services in English, Russian, and Arabic. These services cover complex consultations for bone marrow transplantation and CAR T-cell therapy to ensure patient safety.

• Multilingual coordination: Staff at Hadassah Medical Center assist with medical visas and documentation.
• Language accessibility: Russian and Arabic speakers access dedicated translators for critical treatment discussions.
• Treatment range: Support extends to patients undergoing chemotherapy costing $2,400 to $5,500.
• Specialized translation: Centers provide accurate translation for bone marrow transplants and genomic reporting.

Bookimed Expert Insight: Israeli hospitals like Sheba and Sourasky handle massive patient volumes, with Sheba serving 1,500,000 people annually. Our data shows that because these are large academic institutions, they have permanent in-house translation departments. This is a major advantage over smaller clinics where you might wait days for a freelance interpreter to arrive for your results.

Patient Consensus: Patients note that while Russian and English support is very common, it is wise to confirm interpreter availability for specific appointment times. Many suggest looking into local NGOs like Ezer Mizion, which can sometimes help with specialized transport or additional community support during long stays.

Israel hosts several global transplant and cellular therapy hubs for international patients, primarily in Tel Aviv, Jerusalem, Ramat Gan, and Haifa. These JCI-accredited centers specialize in bone marrow transplantation (BMT) and CAR T-cell therapy. Leading institutions include Sheba Medical Center, Hadassah Medical Center, and Sourasky Medical Center (Ichilov).

• Sheba Medical Center: Located in Ramat Gan. It is a global leader in CAR T-cell therapy.
• Hadassah Medical Center: Based in Jerusalem. It specializes in pediatric BMT and rare blood diseases.
• Sourasky Medical Center: Situated in Tel Aviv. It offers advanced gene-edited stem cell treatments.
• Rambam Medical Center: Located in Haifa. It provides haploidentical transplants for patients without matches.

Bookimed Expert Insight: Israeli centers like Sheba and Sourasky operate 1,500 to 2,000 beds. This high volume allows for dedicated pediatric subdivisions. Dr. Polina Stepensky at Hadassah has performed 3,500+ transplants alone. Patients should choose clinics with on-site cell manufacturing to reduce treatment wait times significantly.

Patient Consensus: Patients emphasize the need to plan for a 4–6 week stay. They also recommend having all medical records translated into English or Hebrew before arriving for treatment.

Israeli hematology-oncology centers typically operate on a direct-pay basis for international patients. Facilities like Sourasky Medical Center (Ichilov) and Hadassah Medical Center require upfront payment via wire transfer or credit card. Patients then submit detailed invoices to their insurers for reimbursement after treatment.

• Payment methods: Clinics accept wire transfers, major credit cards, and cash in USD or ILS.
• Local insurance: Harel Insurance is the primary local provider that may allow for direct billing.
• Travel insurance caps: Standard policies often cap oncology coverage at 50,000 to 100,000 USD.
• Reimbursement documents: Hospitals provide transparent, itemized invoices essential for successful foreign insurance claims.

Bookimed Expert Insight: Our data shows that while public centers like Rambam Medical Center serve nearly 1,000,000 patients annually, they rarely bill foreign insurers directly for elective oncology. Private facilities like Assuta Medical Center offer more flexibility in choosing a specific attending physician. This choice is vital because having a primary doctor facilitates the detailed medical necessity letters required for insurance appeals.

Patient Consensus: Patients note that even with high-end international coverage, they usually pay the full amount out of pocket first. They recommend getting all medical documents translated into English immediately to speed up the reimbursement process with their home providers.